J 2018

East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort

AKIYAMA, E., L.N.L. VAN AELST, M. ARRIGO, J. LASSUS, O. MIRO et. al.

Basic information

Original name

East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort

Authors

AKIYAMA, E. (250 France), L.N.L. VAN AELST (250 France), M. ARRIGO (250 France), J. LASSUS (246 Finland), O. MIRO (724 Spain), J. CELUTKIENE (440 Lithuania), D.J. CHOI (410 Republic of Korea), A.. COHEN-SOLAL (250 France), S. ISHIHARA (250 France), K. KAJIMOTO (392 Japan), S. LARIBI (250 France), A.P. MAGGIONI (380 Italy), J. MOTIEJUNAITE (250 France), C. MUELLER (756 Switzerland), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), J.J. PARK (410 Republic of Korea), N. SATO (392 Japan), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), J. ZHANG (156 China), Y.H. ZHANG (156 China), K. KIMURA (392 Japan), K. TAMURA (392 Japan), E. GAYAT (250 France) and A. MEBAZAA (250 France, guarantor)

Edition

European Journal of heart Failure, Hoboken, Wiley, 2018, 1388-9842

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 12.129

RIV identification code

RIV/00216224:14110/18:00103656

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ejhf.1152

UT WoS

000434273000019

Keywords in English

acute heart failure

Tags

14110211, EL OK, rivok

Tags

International impact, Reviewed
Změněno: 9/2/2019 22:23, Soňa Böhmová

Abstract

V originále

Acute heart failure (AHF) is a major health problem worldwide and trials to assess novel therapies are increasingly global, as a means to reduce costs, expedite timelines, provide broad applicability, and satisfy regulatory authorities.The significant geographic differences in patient characteristics, outcomes, and treatment effect may affect trial results and raise important questions about generalizability of the results to a broader population.
Displayed: 12/11/2024 09:05